Dropps UltraWash Plus biobased dishwasher detergent pods claim to give big-brand detergents a run for their money. We put them to the test.

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, and valuation discounts.

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

Novo Nordisk NOVO.B 1.19% plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

By Amina Niasse and Mariam Sunny (Reuters) -Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

June 26 (Reuters) - Novo Nordisk (NOVOb.CO) said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the U.S. company is using 'deceptive marketing' to sell copycat versions of its obesity ...

Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers, and that direct access to Wegovy won't be available via NovoCare Pharmacy to Hims & Hers members.

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial results on Monday trading.

Drugmaker Novo Nordisk said it is halting its agreement with telehealth company Hims & Hers after less than two months, citing deceptive marketing and the selling of knock-off versions of its b… ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.